IbogaineAdvisor.
About All articles
Policy Tracker

The ibogaine policy landscape — as it moves.

Federal scheduling, state legislation, and the international legal landscape — tracked as it changes. When a bill passes, a trial is funded, or a jurisdiction moves, we cover it. Without a lobbying position.

We report policy developments without advocating for a specific outcome.
Legal status is jurisdiction-specific and changes. Verify current status before making decisions.
We cover setbacks and stalled legislation alongside wins.
Clinical evidence and policy are tracked separately — correlation is not causation.
Sched. I
Federal status — ibogaine remains Schedule I in the United States
2026
Mississippi passes first state ibogaine research bill
3+
Countries where ibogaine is legally available
Last updated May 2026. Mississippi SB 2161 signed into law. Federal status unchanged: Schedule I.
Recent Coverage

What's moved lately

Reference · May 2026

Schedule I Means One Thing on Paper. Here's What It Actually Means for Ibogaine.

Schedule I is supposed to mean two things: high potential for abuse, no accepted medical use. For ibogaine, both are arguable. What the designation actually does, why ibogaine ended up under it, and what would have to happen to move it.

13 min read Read →
Breaking · May 2026

Mississippi Passes First State Ibogaine Research Bill — Bipartisan

SB 2161 passed the Mississippi legislature with broad bipartisan support and was signed into law in May 2026 — making Mississippi the first state to formally authorize ibogaine research. What the bill does, what it doesn't do, and what it signals for federal momentum.

8 min read Read →
Analysis · January 2025

The Trump Executive Order on Veterans and Psychedelic Therapy

In January 2025, the Trump administration issued an executive order directing the VA and DoD to explore psychedelic therapies — including ibogaine — for veterans with PTSD and TBI. What the order actually mandates, what it leaves open, and what it means for research funding.

10 min read Read →
Landscape Tracker

Where things stand

A reference snapshot of ibogaine's legal and regulatory status across key jurisdictions. This tracker is updated as status changes — not a substitute for legal advice.

Jurisdiction Status summary Status
United States (Federal)
Schedule I controlled substance. No approved medical use. Possession and distribution federal crimes.
Schedule I
Mississippi
SB 2161 signed 2026. Authorizes state-funded ibogaine research. Does not legalize treatment.
Passed
Texas
$50M research initiative proposed with veteran advocacy backing (Rick Perry, Marcus Luttrell, Americans for Ibogaine). Legislation active.
Active
VA / DoD (Federal)
2025 Executive Order directs VA and DoD to explore psychedelic therapies for veterans. Research funding being allocated.
In progress
Mexico
Ibogaine is unscheduled and legal. The primary destination for treatment-seeking Americans. No federal prohibition.
Legal
Netherlands
Ibogaine is unscheduled. Legal to purchase and possess. Some clinics operate openly, particularly in Amsterdam.
Legal
Brazil
Ibogaine is unscheduled and legal. Growing treatment community. No federal prohibition.
Legal
Canada
Ibogaine is a Schedule III controlled substance. Possession requires authorization. Research exemptions available.
Controlled
Connected coverage
All policy coverage →
From Research Hub

How clinical trial results drive the policy conversation

The Stanford PTSD study didn't just produce data — it changed what legislators were willing to say out loud. The relationship between research outcomes and regulatory movement.

Read the study analysis →
Context

What Schedule I actually means — and what it doesn't

Schedule I means no currently accepted medical use and a high potential for abuse. It does not mean ibogaine is more dangerous than Schedule II drugs. The history and implications of ibogaine's classification.

Read the explainer →

Policy moves fast. We track it.

When legislation passes, a trial is funded, or a jurisdiction changes — you'll know.